ABOUT INSEPTION GROUP
inSeption Group is a global full-service outsourcing organization built upon a foundational culture of exceptional service and quality.
This culture attracts a subset of industry experts who value your assets as much as you do and take personal responsibility for delivering on what has been promised. Our ability to integrate these dedicated professionals into your teams results in unmatched execution and continuity.
inSeption Group offers full-service outsourcing, functional service provider solutions, and consulting services specializing in oncology, hematology, neurodegenerative disorders, rare disease, and cell and gene therapy.
VIDEOS
-
Explore some of the major challenges that medical writing submission specialists face today and strategies that can consistently set the stage for success.
-
Delve into the significance of adept interpersonal leadership within your drug safety program, shedding light on the operational and financial benefits that stem from fostering a collaborative environment.
-
Watch this presentation to equip stakeholders with actionable strategies and a comprehensive understanding of the evolving clinical trial management landscape in the context of ICH guidelines.
-
Everything we do is driven to challenge the status quo in the current outsourcing paradigm. inSeption is a home for clients and professionals who have been stifled by mainstream, high-volume, commoditized outsourcing models.
CONTACT INFORMATION
inSeption Group
870 W Main Street
Lansdale, PA 19446
UNITED STATES
Phone: (267) 498-5092
FEATURED ARTICLES
- Diverse Mentorship Models Create Multiple Paths To Employee Success
- How To Establish Effective, Scalable Drug Safety Ops Across Vendors
- How To Unlock The Secret To Repeatable, Scalable Low Turnover
- Treating Deficiencies In Employee Training And Mentorship
- Shifting The Approach: 4 Tactics For ICH E6(R3) Implementation
- The Write Side Of AI: Augmenting Capabilities, Not Replacing Them
- Accelerated Development: Gene Therapy Vs. Small Molecule
- The Power And Potential Of RBM In Clinical Trials
- Remote Work Success Is Built On Pre-Site And Site Initiation Visits
- Rare Disease Clinical Endpoints: Ingenuity Meets Practicality
- Gene Therapy Natural History Studies: Benefits, Timing, And Execution
- Biotech Files NDA Following Risk-Based Mock Inspection
- Regulatory Submission Crisis Rescue: When To Take Action
- What Quality Control In Medical Writing Means, And Why It Matters
- Time, Logistics, And Manufacturing In Autologous Cell Therapy Clinical Trials
- CRAs Must Evolve Alongside Oncology Therapeutics
- Enhancing Autologous Cell Therapy Trials Through Collaborative Protocol Design
- Remote Clinical Trial Monitoring: CRA Success In An Era Of Autonomy
- Why Site And Partner Communications Are Critical To Autologous Cell Therapy Clinical Trials
- Round 2: Mastering NDA Submission And A Resubmission Rescue Mission
MYTHBUSTERS
-
Large CROs have a vast pool of resources and a subset of amazingly talented people. However, the decision to select such a CRO on the concept that they have access to the best talent, and the hope that those resources will be assigned to your study, is flawed.
-
Most quantitative and qualitative studies seeking to understand what creates fear and anxiety in humans conclude with some version of the same 4 key criteria: Lack of Control, Large Consequence, Sudden Occurrence, and Unfamiliarity. In our outsourcing industry, it is never an easy decision to select a partner when trying to run complex sequential trials. The need to gain regulatory approval for the treatments you have dedicated yourself to providing, coupled with the need to find a capable, reliable, and fair Contract Research Organization is quite daunting.
-
The theory of Corporate Memory is easy to understand and agree with – the better you record and understand recurring actions the better you will perform those actions. Read why Capitalizing on corporate memory might work at an individual level but is nothing more than a myth and an empty promise in the complex changing world of drug clinical studies.
-
Have you ever asked yourself why you take comfort with governance agreements? They're created to "protect" you when your CRO fails - and even then, what can you realistically do? Find out the answers here.
E-BOOKS
-
Gene therapy has existed for decades, but the field is not as mature as it may seem. Here, the author provides essential insights and strategies for overcoming gene therapy development challenges.
-
Making the right outsourcing decision can significantly contribute to the success and growth of your program, providing essential support and resources that empower it to thrive in its objectives and endeavors.
-
Delve into four articles regarding dissecting the critical resources, processes, and key stakeholders essential for the successful completion of an ACT clinical trial.
-
Discover how biopharmaceutical sponsors in clinical trials leverage real-time data analytics and conduct comprehensive gap analyses to improve trial efficiency and overcome study challenges, such as patient recruitment and retention, risk mitigation, and evolving patient expectations.
-
Discover how clinical research services must wade through a bog of incomplete information, and sometimes outright misinformation, when it comes to seeking reliable partnerships.
-
Biopharma companies — particularly smaller or emerging organizations — often are unable to draw maximum value from CROs. This occurs for any number of reasons, several of which are covered in this e-book.